AUS
NZ
UK
CA
USA
IND
Highlights:
Hologic Inc. (HOLX) reports a 4.2% year-over-year growth in Q4 2024 total revenue, reaching $987.9 million.
The company demonstrates strong performance in its molecular diagnostics, breast health, and surgical segments, with notable growth in diagnostics and breast health.
Hologic announces a $250 million accelerated share repurchase program for fiscal year 2025, emphasizing its focus on capital allocation and shareholder value.
Hologic Inc. (NASDAQ:HOLX) posted solid financial results for Q4 2024, reporting total revenue of $987.9 million, a 4.2% increase compared to the previous year. The company saw robust growth across several key segments, with diagnostics revenue rising by 6.2%, reflecting a 9.2% organic growth excluding COVID-related factors. The breast health division also experienced 6.2% revenue growth, with 5.3% organic growth when excluding the impacts of SSI and Endo Matics.
Despite some challenges, such as a significant 54.9% decline in revenue from its skeletal business due to a temporary stop-ship, Hologic reported strong operating and net margins of 30% and 24%, respectively. The company’s total revenue for the fiscal year 2024 reached $4.03 billion, reflecting a 5.3% organic growth, excluding COVID-19-related impacts.
Hologic's fiscal year 2024 non-GAAP earnings per share (EPS) stood at $4.08, a 3% year-over-year increase. The company also prioritized shareholder returns, repurchasing 11.2 million shares for $808 million during the year. For fiscal year 2025, Hologic provided guidance for revenue between $4.15 billion and $4.20 billion, with non-GAAP EPS expected in the range of $4.25 to $4.35.
While Hologic remains optimistic about its performance in 2025, challenges such as IV fluid shortages affecting surgical and breast health procedures, as well as a potential slowdown in its breast health segment due to the upcoming gantry launch, are expected to create headwinds in the first half of the year. The company anticipates a strong recovery in the second half, with margin expansion expected as the impact of these issues subsides.
In addition to these challenges, Hologic is focusing on its respiratory and molecular diagnostics businesses, including continued growth in its BV CV TV assays, which have become a significant revenue driver. The company is also making strategic investments in acquisitions, further strengthening its portfolio and positioning for long-term growth.
